Please assess the completion status of the following clinical trial:

Trial Title: Effect of Sumatriptan on the Postoperative Quality of Recovery After Elective Minimally Invasive Craniotomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients having elective craniotomy for clipping of unruptured intracranial aneurysm~2. Patients having craniotomy and microvascular decompression for cranial nerve neuralgia~3. Age 18-80~4. ASA I -III~Exclusion Criteria:~1. Patients with a known history of hypersensitivity to Sumatriptan or sulphonamides~2. Patients with a known history of Migraine~3. Patients who is on regular treatment with Sumatriptan~4. Patients with history of Ischemic heart disease - Angina, Myocardial infarction.~5. Patients who had rupture of their intracranial aneurysm.~6. Patients with history of severe liver disease.~7. Patients with history of stroke or uncontrolled hypertension~8. Inability to give informed consent~9. Pregnant patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Sumatriptan (Type: EXPERIMENTAL): Subcutaneous injection of sumatriptan (6 mg)
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo (0.9% saline)

Based on this trial design, predict the completion outcome and termination type (if applicable).